Copy to clipboard 
ATEC reported 1Q25 orthopedic sales of $169.2 million, up 22.2% compared to the first quarter of 2024.
The company’s ability to compel surgeon adoption and attract tenured reps is undeniable. ATEC’s surgical revenue grew 24% in the first quarter, many multiples of the market. Revenue from established territories grew 23%, while surgeon users grew 18%. The company also drove record EOS orders in the first quarter.
ATEC has invested heavily in spine and said newly spun out private companies have a long, expensive road ahead.
“If your vocation is spine surgery, you want to be aligned with a company that is dependent upon being great in spine surgery,” said ATEC CEO Pat Miles. “That’s us. We’re unapologetically evangelical about this space. If you’d have told me seven years ago when we started this turnaround, that we’d be sitting here as the largest pure-play spine company with the opportunity to run the table, I’d be surprised. But that’s where we sit today and we can’t be more excited about the opportunity.”
The company expects minimal impact from the current tariffs, totaling under $10 million for the year. Only parts for EOS are subject to tariffs.
For the full year 2025, ATEC expects 20% growth to a total of $734 million and adjusted EBITDA of $78 million.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $137.8 | $110.8 | $27.0 | 24.3% |
| Orthobiologics | $14.4 | $11.8 | $2.6 | 22.2% |
| Enabling Technology | $17.0 | $15.9 | $1.1 | 7.2% |
| Total | $169.2 | $138.5 | $30.7 | 22.2% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $159.1 | $129.8 | $29.3 | 22.5% |
| OUS | $10.1 | $8.6 | $1.4 | 16.6% |
| Total | $169.2 | $138.5 | $30.7 | 22.2% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $169.2 | |
| Cost of Sales | $53.2 | 31.4% |
| Selling and Admin | $127.0 | 75.1% |
| R & D | $16.6 | 9.8% |
| R & D | $16.6 | 9.8% |
| Other | $24.3 | 14.4% |
ATEC reported 1Q25 orthopedic sales of $169.2 million, up 22.2% compared to the first quarter of 2024.
The company's ability to compel surgeon adoption and attract tenured reps is undeniable. ATEC's surgical revenue grew 24% in the first quarter, many multiples of the market. Revenue from established territories grew 23%, while surgeon...
ATEC reported 1Q25 orthopedic sales of $169.2 million, up 22.2% compared to the first quarter of 2024.
The company’s ability to compel surgeon adoption and attract tenured reps is undeniable. ATEC’s surgical revenue grew 24% in the first quarter, many multiples of the market. Revenue from established territories grew 23%, while surgeon users grew 18%. The company also drove record EOS orders in the first quarter.
ATEC has invested heavily in spine and said newly spun out private companies have a long, expensive road ahead.
“If your vocation is spine surgery, you want to be aligned with a company that is dependent upon being great in spine surgery,” said ATEC CEO Pat Miles. “That’s us. We’re unapologetically evangelical about this space. If you’d have told me seven years ago when we started this turnaround, that we’d be sitting here as the largest pure-play spine company with the opportunity to run the table, I’d be surprised. But that’s where we sit today and we can’t be more excited about the opportunity.”
The company expects minimal impact from the current tariffs, totaling under $10 million for the year. Only parts for EOS are subject to tariffs.
For the full year 2025, ATEC expects 20% growth to a total of $734 million and adjusted EBITDA of $78 million.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $137.8 | $110.8 | $27.0 | 24.3% |
| Orthobiologics | $14.4 | $11.8 | $2.6 | 22.2% |
| Enabling Technology | $17.0 | $15.9 | $1.1 | 7.2% |
| Total | $169.2 | $138.5 | $30.7 | 22.2% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $159.1 | $129.8 | $29.3 | 22.5% |
| OUS | $10.1 | $8.6 | $1.4 | 16.6% |
| Total | $169.2 | $138.5 | $30.7 | 22.2% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $169.2 | |
| Cost of Sales | $53.2 | 31.4% |
| Selling and Admin | $127.0 | 75.1% |
| R & D | $16.6 | 9.8% |
| R & D | $16.6 | 9.8% |
| Other | $24.3 | 14.4% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
